.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ sophisticated breast cancer cells as well as energetic or dependable brain metastases revealed regular intracranial task and also wide spread efficacy of T-DXd.